Webinar: Science, Business, and Vaccine Development to Combat the Pandemic Panelist Transcript
Webinar: Science, Business, and Vaccine Development to Combat the Pandemic Panelist Transcript Moderator • Tarun Khanna, Jorge Paulo Lemann Professor, Harvard Business School; Director, The Mittal Insti- tute Panelists • Gagandeep Kang, Executive Director, Translational Health Science and Technology Institute & Vice Chairperson of The Coalition for Epidemic Preparedness Innovations • Umang Vohra, Managing Director & Global Chief Executive Officer, Cipla Ltd. • David E. Bloom, Clarence James Gamble Professor of Economics & Demography, Harvard T.H. Chan School of Public Health Through the lens of a contemporary case study in the South Asia context, panelists will discuss the geopoli- tics of how vaccines are developed, the funding and distribution methods that are critical to the effort, and the global alliances that facilitate this in the world today. BEGIN TRANSCRIPTION: Inakshi Sobti: Good evening and welcome. My name is Inakshi Sobti, it’s wonderful to see participants join us from India, Pakistan, Sri Lanka, Bangladesh, Nepal, the Middle East, the US, even the Bahamas. On behalf of the Harvard Business School India Research Center and our faculty here in Boston, our esteemed col- leagues from Harvard Business Publishing, the Lakshmi Mittal South Asia Institute, and our panelists, thank you for joining us. Welcome to the second conversation in our webinar series ‘Leadership Perspectives for a Changing World.’ With over 7 million people diagnosed with Covid-19 and over 400,000 deaths globally, it is no surprise that all eyes are fixed with hope and anticipation on the scientific community and the pharmaceuticals industry. Today we have a stellar panel sharing their thoughts on how science and business are collaborating to develop vaccines and drugs to combat the pandemic.
[Show full text]